A Strategy of Success in the Treatment of Prostate Cancer – 3
SIGN UP FOR OUR NEWSLETTER


Quick Search

Reset

PCRI Insights July, 2002 vol. 5, no. 1
By Stephen B. Strum, MD, FACP
Page
<<
  1  2  3

References
1. Batson OV: The function of the vertebral veins and their role in the spread of metastases. Ann Surg 112:138-149, 1940.

2. Steinberg GD, Carter BS, Beaty TH, et al: Family history and the risk of prostate cancer. Prostate 17:337-47, 1990.

3. Brooks JD, Metter EJ, Chan DW, et al: Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166:2034-8, 2001.

4. Clark LC, Combs GF, Jr., Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama 276:1957-63, 1996.

5. Heinonen OP, Albanes D, Virtamo J, et al: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440-6, 1998.

6. Fleshner N, Fair WR, Huryk R, et al: Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 161:1651-4, 1999.

7. Helzlsouer KJ, Huang HY, Alberg AJ, et al: Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92:2018-23, 2000.

8. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277:1452-5, 1997.

9. Crawford ED, Chia D, Andriole G, et al: PSA changes as related to the initial PSA: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Proc Am Soc Clin Oncol 20:177a, 2001.

10. Keetch DW, McMurtry JM, Smith DS, et al: Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 156:428-31, 1996.

11. Chen ME, Troncoso P, Johnston D, et al: Prostate cancer detection: relationship to prostate size. Urology 53:764-8, 1999.

12. Aihara M, Lebovitz RM, Wheeler TM, et al: Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol 151:1558-64, 1994.

13. D’Amico AV, Propert KJ: Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 35:273-9, 1996.

14. D’Amico AV, Chang H, Holupka E, et al: Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 49:385-91, 1997.

15. Stamey TA, McNeal JE, Yemoto CM, et al: Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395-400, 1999. 16. Matsushima H, Kitamura T, Goto T, et al: Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol 158:2278-83, 1997.

17. Shariat SF, Shalev M, Menesses-Diaz A, et al: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19:2856-64, 2001.

18. Steinberg DM, Sauvageot J, Piantadosi S, et al: Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21:566-76, 1997.

19. Wurzer JC, Al-Saleem TI, Hanlon AL, et al: Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: correlation of pathologic findings, analysis of cost, and impact on treatment. Cancer 83:753-9, 1998.

20. Carlson GD, Calvanese CB, Kahane H, et al: Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. Urology 51:525-9, 1998.

21. Kronz JD, Silberman MA, Allsbrook WC, et al: A web-based tutorial improves practicing pathologists’ Gleason grading of images of prostate carcinoma specimens obtained by needle biopsy: validation of a new medical education paradigm. Cancer 89:1818-23, 2000.

22. Badalament RA, Miller MC, Peller PA, et al: An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 156:1375-80, 1996.

23. Borirakchanyavat S, Bhargava V, Shinohara K, et al: Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy. Urology 50:373-8, 1997.

24. Conrad S, Graefen M, Pichlmeier U, et al: Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol 159:2023-9, 1998.

25. D’Amico AV, Whittington R, Malkowicz SB, et al: Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 55:572-7, 2000.

26. D’Amico AV, Schultz D, Silver B, et al: The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49:679-84, 2001.

27. Grossfeld GD, Chang JJ, Broering JM, et al: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 165:851-6, 2001.

28. Huland H, Hammerer P, Henke RP, et al: Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized proclinistatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. J Urol 155:1344-7, 1996.

29. Peller PA, Young DC, Marmaduke DP, et al: Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 75:530-8, 1995. 30. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al: Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/ recurrent detectable PSA after radical prostatectomy. Urology 44:371-6, 1994.

31. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al: [Role of biological and anatomo-pathologic criteria in the prognosis evaluation of patients before and after radical prostatectomy]. Prog Urol 4:673-82, 1994.

32. Wills ML, Sauvageot J, Partin AW, et al: Ability of sextant biopsies to predict radical prostatectomy stage. Urology 51:759-64, 1998.

33. Ahlgren G, Lindholm K, Falkmer U, et al: A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate. Urology 50:379-84, 1997.

34. Badalament RA, O’Toole RV, Young DC, et al: DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 67:3014-23, 1991.

35. Carmichael MJ, Veltri RW, Partin AW, et al: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 153:1015-9, 1995.

36. Currin SM, Lee SE, Walther PJ: Flow cytometric analysis of comedocarcinoma of the prostate: an uncommon histopathological variant of prostatic adenocarcinoma. J Urol 140:96-100, 1988.

37. Erbersdobler A, Hammerer P, Huland H, et al: Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. J Urol 158:1594- 8, 1997.

38. Forsslund G, Esposti PL, Nilsson B, et al: The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 69:1432-9, 1992.

39. Gauwitz MD, Pollack A, el-Naggar AK, et al: The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 28:821-8, 1994.

40. Greene DR, Rogers E, Wessels EC, et al: Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 151:1301-7, 1994.

41. Greene DR, Wheeler TM: Clinical relevance of the individual prostate cancer focus. Cancer Invest 12:425-37, 1994.

42. Hawkins CA, Bergstralh EJ, Lieber MM, et al: Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy. Urology 46:356-64, 1995.

43. Henke RP, Hammerer P, Graefen M, et al: Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma. Cancer 83:977-88, 1998.

44. Hussain MH, Powell I, Zaki N, et al: Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer. Cancer 72:3012-9, 1993.

45. Khoo VS, Pollack A, Cowen D, et al: Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41:166-72, 1999.

46. Lee SE, Currin SM, Paulson DF, et al: Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol 140:769-74, 1988.

47. Lerner SE, Blute ML, Bergstralh EJ, et al: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 156:137-43, 1996.

48. Lerner SE, Blute ML, Zincke H: Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 14:12- 20; discussion 21, 1996.

49. Miller J, Horsfall DJ, Marshall VR, et al: The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma. J Urol 145:1192-6, 1991.

50. Phillips JL, Hayward SW, Wang Y, et al: The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 61:8143-9, 2001.

51. Pollack A, Zagars GK, el-Naggar AK, et al: Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer 73:1895-903, 1994.

52. Pollack A, Zagars GK, el-Naggar AK, et al: Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 44:711-8, 1994.

53. Ross JS, Figge H, Bui HX, et al: Prediction of pathologic stage and post-prostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 74:2811-8, 1994.

54. Ross JS, Figge HL, Bui HX, et al: E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 7:835-41, 1994.

55. Scrivner DL, Meyer JS, Rujanavech N, et al: Cell kinetics by bromodeoxyuridine labeling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies. J Urol 146:1034-9, 1991.

56. Shankey TV, Jin JK, Dougherty S, et al: DNA ploidy and proliferation heterogeneity in human prostate cancers. Cytometry 21:30-9, 1995.

57. Song J, Cheng WS, Cupps RE, et al: Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy. J Urol 147:794-7, 1992.

58. Stege R, Tribukait B, Lundh B, et al: Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol 148:833-7, 1992.

59. Tinari N, Natoli C, Angelucci D, et al: DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. Cancer 71:1289-96, 1993.

60. van den Ouden D, Tribukait B, Blom JH, et al: Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 150:400-6, 1993.

61. van der Poel HG, Oosterhof GO, Schaafsma HE, et al: Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology 49:652-7, 1997.

62. Berruti A, Dogliotti L, Bitossi R, et al: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164:1248-53, 2000.

63. Koga H, Naito S, Koto S, et al: Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39:1-7, 1999.

64. Takeuchi S, Arai K, Saitoh H, et al: Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 156:1691-5, 1996.

65. Smith MR, McGovern FJ, Fallon MA, et al: Low bone mineral density in hormone- naive men with prostate carcinoma. Cancer 91:2238-45, 2001.

66. Schatzl G, Madersbacher S, Thurridl T, et al: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47:52-8, 2001.

67. Hoffman MA, De Wolf WC, A M: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163:824-7, 2000.

68. Zagars GK, Pollack A, von Eschenbach AC: Serum testosterone–a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49:327-34, 1997.

69. Kitahara S, Yoshida K, Ishizaka K, et al: Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. Endocr J 44:527-32, 1997.

70. Oefelein MG, Feng A, Scolieri MJ, et al: Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56:1021-4, 2000.

71. Oefelein MG, Cornum R: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164:726-9, 2000.

72. Dattoli M, Wallner K, True L, et al: Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 45:853-6, 1999.

73. Moul JW, Connelly RR, Perahia B, et al: The contemporary value of pre-treatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol 159:935-40, 1998.

74. Han M, Piantadosi S, Zahurak ML, et al: Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57:707-11, 2001.

75. Roy AV, Brower ME, Hayden JE: Sodium thymolphthalein monophosphate: A new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 17:1093-1102, 1971.

76. Batuello JT, Gamito EJ, Crawford ED, et al: Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. Urology 57:481-5, 2001.

77. Han M, Snow PB, Epstein JI, et al: A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 56:994-9, 2000.

78. Bostwick DG, Burke HB: Prediction of individual patient outcome in cancer: comparison of artificial neural networks and Kaplan–Meier methods. Cancer 91:1643-6, 2001.

79. Babaian RJ, Fritsche H, Ayala A, et al: Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 56:1000-6, 2000.

80. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinistatic cal stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-4, 1993.

81. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. Jama 277:1445-51, 1997.

82. Partin AW, Mangold LA, Lamm DM, et al: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843-8, 2001.

83. Ziada AM, Lisle TC, Snow PB, et al: Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. Cancer 91:1653-60, 2001.

84. Tewari A, Issa M, El-Galley R, et al: Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol 5:163-9, 2001.

85. Porter C, O’Donnell C, Crawford ED, et al: Artificial neural network model to predict biochemical failure after radical prostatectomy. Mol Urol 5:159-62, 2001.
<<  1  2  3